Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma

Leukemia volume 28, pages 1885–1891 (2014)Cite this article

Subjects

Abstract

Peripheral T-cell lymphomas (PTCLs) receiving conventional treatment have a poor clinical outcome. We conducted a phase II study to evaluate the feasibility and efficacy of chemo-immunotherapy in young (⩽60 years old, Clin A study) and elderly (>60 and ⩽75 years old, Clin B study) patients with newly diagnosed PTCL. Clin A patients (n=61) received two courses of CHOP (cyclophosphamide, adriamycin, vincristine, prednisone)-21 with alemtuzumab (AL, 30 mg) followed by two courses of high-dose chemotherapy. On the basis of donor availability, patients in response received allogeneic (allo) or autologous (auto) stem cell transplantation (SCT). Clin B patients (n=25) received six courses of CHOP-21 and AL (10 mg). Clin A responding patients were 38 of 61 (62%) and received alloSCT (n=23) or autoSCT (n=14); one complete remission (CR) patient was not transplanted. At a median follow-up of 40 months, the 4-year overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) rates were 49, 44 and 65%, respectively. In Clin B study, the response rate was 72%. At a median follow-up of 48 months, the 4-year OS, PFS and DFS rates were 31, 26 and 44%, respectively. In conclusion, front-line alloSCT or autoSCT is effective in prolonging DFS in young patients; AL in elderly improved response with no survival benefit.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Foss FM, Zinzani PL, Vose GM, Gascoyne RD, Rosen ST, Tobinai K et al. Peripheral T-cell lymphomas. Blood 2011; 117: 6756–6767.

    Article  CAS  Google Scholar 

  2. International T cell lymphomas Project. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124–4130.

    Article  Google Scholar 

  3. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010; 116: 3418–3425.

    Article  CAS  Google Scholar 

  4. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12: 7174–7179.

    Article  CAS  Google Scholar 

  5. Geissinger E, Bonzheim I, Roth S, Rosenwald A, Muller-Hermelink HK, Rudiger T . CD52 expression in peripheral T-cell lymphomas determined by combine immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma 2009; 50: 1010–1016.

    Article  CAS  Google Scholar 

  6. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316–2323.

    Article  CAS  Google Scholar 

  7. Kluin-Nelemans HC, Kooy MM, Lugtenburg PJ, Van Putten WLJ, Luten M, Oudejans J et al. Intensified alemtuzumab–CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 2011; 22: 1595–1600.

    Article  CAS  Google Scholar 

  8. Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol 2007; 60: 129–134.

    Article  CAS  Google Scholar 

  9. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533–1538.

    Article  CAS  Google Scholar 

  10. Rodrıguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The GelTamo Study Group. Eur J Haematol 2007; 79: 32–38.

    Article  Google Scholar 

  11. Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19: 958–963.

    Article  CAS  Google Scholar 

  12. Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106–113.

    Article  CAS  Google Scholar 

  13. D'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson A et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093–3099.

    Article  CAS  Google Scholar 

  14. Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176.

    Article  Google Scholar 

  15. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520–526.

    Article  CAS  Google Scholar 

  16. Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.

    Article  Google Scholar 

  17. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001.

    Google Scholar 

  18. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2008.

    Google Scholar 

  19. Todeschini G, Tecchio C, Pasini F, Benedetti F, Cantini M, Crippa C et al. Hyperfractionated cyclophosphamide with high-doses of arabinosylcytosine and methotrexate (HyperCHiDAM Verona 897). Cancer 2005; 104: 555–560.

    Article  CAS  Google Scholar 

  20. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99: 75–82.

    Article  CAS  Google Scholar 

  21. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999; 17: 1244–1253.

    Article  CAS  Google Scholar 

  22. Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10.

    Article  CAS  Google Scholar 

  23. Gray RJ . A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141–1154.

    Article  Google Scholar 

  24. Klein JP, Rizzo JD, Zhang MJ, Keiding N . Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28: 1001–1011.

    Article  CAS  Google Scholar 

  25. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American Institution by the WHO classification. Ann Oncol 2004; 15: 1467–1475.

    Article  CAS  Google Scholar 

  26. Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer 2012; 48: 3223–3331.

    Article  CAS  Google Scholar 

  27. Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T-cell lymphoma. Biol Blood Marrow Transplant 2013; 19: 602–606.

    Article  CAS  Google Scholar 

  28. Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, Fenske TS et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 2013; 31: 3100–3109.

    Article  Google Scholar 

  29. Lemonnier F, Couronné L, Parrens M, Jaïs JP, Travert M, Lamant L et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012; 120: 1466–1469.

    Article  CAS  Google Scholar 

  30. Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol 2013; 31: 3019–3025.

    Article  Google Scholar 

  31. Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013; 31: 104–110.

    Article  CAS  Google Scholar 

  32. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182–1189.

    Article  CAS  Google Scholar 

  33. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30: 631–636.

    Article  CAS  Google Scholar 

  34. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190–2196.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant from AIFA (Agenzia Italiana del Farmaco) of the Ministry of Health, and in part by AIRC (Associazione Italiana per la Ricerca sul Cancro). We thank Fondazione Michelangelo Milano for the GCP conduction of this clinical trial.

Author information

Authors and Affiliations

  1. Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

    P Corradini & A Dodero

  2. University of Milan, Milano, Italy

    P Corradini

  3. Division of Hematology, Ospedale San Giovanni Battista, Torino, Italy

    U Vitolo & B Bruno

  4. Division of Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

    A Rambaldi

  5. Department of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

    R Miceli

  6. Department of Hematology, University of Udine, Udine, Italy

    F Patriarca

  7. Department of Hematology, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy

    A Gallamini

  8. Department of Hematology, Ospedale Umberto-Torrette di Ancona, University of Ancona, Ancona, Italy

    A Olivieri

  9. Department of Hematology, Policlinico G.B. Rossi, Verona, Italy

    F Benedetti & G Todeschini

  10. Department of Hematology, Ospedale di Brescia, Brescia, Italy

    G Rossi

  11. Department of Hematology, Ospedale di Alessandria, Alessandria, Italy

    F Salvi

  12. Department of Hematology, Fondazione IRCCS Ca’ Granda OM Policlinico and University of Milano, Milano, Italy

    L Baldini

  13. Department of Oncology, Ospedale San Raffaele, Milano, Italy

    A Ferreri

  14. Department of Bone Marrow Transplantation, Azienda Ospedaliera Ospedali Riuniti, Villa Sofia, Cervello, Palermo, Italy

    C Patti

  15. Department of Hematology, Azienda Ospedaliera Mauriziano, Torino, Italy

    C Tarella

  16. Department of Anatomic-Pathology, University of Bologna, Bologna, Italy

    S Pileri

Authors
  1. P Corradini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U Vitolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Rambaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Miceli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Patriarca
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Gallamini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. F Benedetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Todeschini
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Salvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B Bruno
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. L Baldini
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A Ferreri
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. C Patti
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. C Tarella
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. S Pileri
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. A Dodero
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of Fondazione Italiana Linfomi

Corresponding author

Correspondence to A Dodero.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

CP, TC and DA designed the study, analyzed the data and wrote the manuscript. VU, RA, MR, PF, GA, OA, BF, TG, RG, SF, BB, BL, FA, PC, TC and PS contributed to obtain study materials, contributed to draft the manuscript, and gave their approval of the final manuscript.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corradini, P., Vitolo, U., Rambaldi, A. et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 28, 1885–1891 (2014). https://doi.org/10.1038/leu.2014.79

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.79

This article is cited by

Search

Advanced search

Quick links